Multiplex Immunofluorescence: A Powerful Tool in Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Traditional immunohistochemistry (IHC) is vital for cancer diagnosis and therapy but limited to single-marker detection per section.
• The rise of immunotherapy necessitates advanced techniques for comprehensive tumor microenvironment analysis.
• Simultaneous detection of multiple biomarkers is crucial for predicting and assessing immunotherapy response.

Purpose of the Study:

• To review emerging multiplex immunohistochemistry (mIHC) and multiplex immunofluorescence (mIF) technologies.
• To discuss the application of these multiplex techniques in cancer immunotherapy research.
• To highlight the advantages of multiplex fluorescent immunohistochemistry (mfIHC) in this field.

Main Methods:

• Review of current multiplex immunohistochemistry (mIHC) and multiplex immunofluorescence (mIF) technologies.
• Analysis of how these methods facilitate simultaneous biomarker detection.
• Focus on multiplex fluorescent immunohistochemistry (mfIHC) applications.

Main Results:

• Multiplex immunohistochemistry (mIHC)/multiplex immunofluorescence (mIF) allows for multi-marker labeling on a single tissue section.
• Multiplex fluorescent immunohistochemistry (mfIHC) demonstrates enhanced performance in cancer immunotherapy studies.
• These techniques provide deeper insights into tumor heterogeneity and immune cell infiltration.

Conclusions:

• Multiplex immunohistochemistry represents a significant advancement over traditional IHC for cancer research.
• Multiplex fluorescent immunohistochemistry (mfIHC) is a powerful tool for understanding tumor biology and guiding immunotherapy.
• Further development and application of mIHC/mIF are essential for optimizing cancer treatment strategies.